These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22547083)

  • 41. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
    Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
    Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic variation in human P450 oxidoreductase.
    Miller WL; Huang N; Agrawal V; Giacomini KM
    Mol Cell Endocrinol; 2009 Mar; 300(1-2):180-4. PubMed ID: 18930113
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study.
    Dujic T; Zhou K; Donnelly LA; Leese G; Palmer CNA; Pearson ER
    Diabetes Obes Metab; 2018 Jan; 20(1):211-214. PubMed ID: 28656666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Loss of Protein Stability and Function Caused by P228L Variation in NADPH-Cytochrome P450 Reductase Linked to Lower Testosterone Levels.
    Rojas Velazquez MN; Noebauer M; Pandey AV
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077536
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions.
    Zi J; Liu D; Ma P; Huang H; Zhu J; Wei D; Yang J; Chen C
    Drug Metab Pharmacokinet; 2010; 25(4):343-50. PubMed ID: 20814155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amino acid residues affecting the activities of human cytochrome P450 2C9 and 2C19.
    Niwa T; Kageyama A; Kishimoto K; Yabusaki Y; Ishibashi F; Katagiri M
    Drug Metab Dispos; 2002 Aug; 30(8):931-6. PubMed ID: 12124312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis.
    Ieiri I; Tainaka H; Morita T; Hadama A; Mamiya K; Hayashibara M; Ninomiya H; Ohmori S; Kitada M; Tashiro N; Higuchi S; Otsubo K
    Ther Drug Monit; 2000 Jun; 22(3):237-44. PubMed ID: 10850388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P.
    Dhir V; Ivison HE; Krone N; Shackleton CH; Doherty AJ; Stewart PM; Arlt W
    Mol Endocrinol; 2007 Aug; 21(8):1958-68. PubMed ID: 17505056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biochemical analysis of mutations in P450 oxidoreductase.
    Pandey AV
    Biochem Soc Trans; 2006 Dec; 34(Pt 6):1186-91. PubMed ID: 17073782
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
    Wang B; Wang J; Huang SQ; Su HH; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase.
    Udhane SS; Parween S; Kagawa N; Pandey AV
    Front Pharmacol; 2017; 8():580. PubMed ID: 28970799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption.
    Chenoweth MJ; Zhu AZ; Sanderson Cox L; Ahluwalia JS; Benowitz NL; Tyndale RF
    Pharmacogenet Genomics; 2014 Mar; 24(3):172-6. PubMed ID: 24448396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase.
    Pandey AV; Flück CE; Mullis PE
    Biochem Biophys Res Commun; 2010 Sep; 400(3):374-8. PubMed ID: 20732302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
    Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
    J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.
    Zhang X; Li L; Ding X; Kaminsky LS
    Drug Metab Dispos; 2011 Aug; 39(8):1433-9. PubMed ID: 21562147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Variability in Loss of Multiple Enzyme Activities Due to the Human Genetic Variation P284T Located in the Flexible Hinge Region of NADPH Cytochrome P450 Oxidoreductase.
    Parween S; Rojas Velazquez MN; Udhane SS; Kagawa N; Pandey AV
    Front Pharmacol; 2019; 10():1187. PubMed ID: 31749697
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase.
    Pandey AV; Kempná P; Hofer G; Mullis PE; Flück CE
    Mol Endocrinol; 2007 Oct; 21(10):2579-95. PubMed ID: 17595315
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system.
    Moutinho D; Marohnic CC; Panda SP; Rueff J; Masters BS; Kranendonk M
    Drug Metab Dispos; 2012 Apr; 40(4):754-60. PubMed ID: 22252407
    [TBL] [Abstract][Full Text] [Related]  

  • 59. No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3.
    Hanatani T; Fukuda T; Onishi S; Funae Y; Azuma J
    Eur J Clin Pharmacol; 2003 Jul; 59(3):233-5. PubMed ID: 12756514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.